MarketMoodz
LLY — Eli Lilly and Company
Is LLY overbought or oversold? Here is the current MarketMoodz read.
Eli Lilly and Company (LLY) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Pharmaceuticals) last closed at $1213.91. The rating moved from Overbought to Neutral on July 3, 2026 and has changed 36 times in the last 90 days.
- Public ratingNeutral (as of July 5, 2026)
- Last close$1213.91
- Rating changesRating changed 36 times in the last 90 days
- Last changeMoved from Overbought to Neutral on July 3, 2026
- SectorHealthcare
- IndustryPharmaceuticals
Latest MarketMoodz coverage
- Innovent, Lilly Expand Verzenios Commercialization in China2026-07-01
- Medicare to Temporarily Cover GLP‑1 Obesity Drugs Starting July 1, 20262026-06-30
- FDA Selects Firms for PreCheck to Speed New Drug Plants2026-06-29
- Chip Stocks Rally as Goldman’s M&A Streak Spurs Rotation2026-06-29
- Medicare's Bridge to Cover GLP‑1 Obesity Drugs — Copay $50, Starts July 12026-06-28
See today's live rating, score and targets
Members see the live hourly rating for LLY — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.